Sheba Medical Center Inks Collaborative Agreement with Regeneron Focusing On Accelerating Oncology Research & Delivering Novel Therapeutics

Sheba Medical Center which highlights the largest “City of Health” medical campus in Israel and a Newsweek “World’s Top 10 Best Hospital,” today announced a new collaboration agreement with Regeneron (NASDAQ: REGN), a leading global biotechnology company, that will focus on oncology research and accelerating the development of potential novel therapeutics to help patients in need.

Regeneron will also sponsor Sheba’s ARC (Accelerate, Redesign and Collaborate) innovation center, where a “personalized medicine” development hub is creating cutting-edge solutions for patient care, and where Regeneron will join Sheba’s HealthTech Valley, a growing global ecosystem focusing on redesigning healthcare by bringing together academia, industry and medicine.

Founded and led for nearly 35 years by physician-scientists, Regeneron’s unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in Regeneron’s laboratories. Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

“The Regeneron team is pleased to collaborate with Sheba in order to accelerate clinical studies of novel oncology therapeutics for patients in need,” said David Weinreich, M.D., Executive Vice President, Global Clinical Development of Regeneron. “As we work to turn innovative science into needed medicines, we will partner with centers of excellence like Sheba that have established best practice clinical trial processes. We will also share knowledge through programs such as our joint Post-Doctoral Research program, because we know that fighting cancer requires cooperation from the best minds around the world.”

“We are excited and proud to partner with Regeneron to accelerate clinical research and to enhance patient access to novel treatments. The agreement exemplifies our mutual desire to improve patient outcomes with an emphasis on creating a better quality of life,” said Professor Yitshak Kreiss, Director General of Sheba Medical Center.

SourceRegeneron
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Tabrecta is the first FDA-approved therapy to treat non small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
The Cor® TRICUSPID ECM® valve has been successfully implanted in the 11th patient enrolled in the expansion by Dr. Marc Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the study.
Thirona notes LungQ 3.0.0 builds on 10 years of clinical trials and 200+ publications to deliver advanced segmentation of pulmonary segments and subsegments.
The Zeta Surgical Cranial Navigation System is a mixed-reality navigation system for neurosurgery, providing surgeons with "GPS-like" guidance with millimetric accuracy in real-time. Zeta's computer vision engine ensures maintained accuracy by automatically registering multiple times a second, accounting for patient movement, and allowing for awake and non-immobilized use in both operative and extra-operative settings.
The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

By using this website you agree to accept Medical Device News Magazine Privacy Policy